2000 SIERRA POINT PARKWAY, SUITE 501, BRISBANE, CA
Agreement and Plan of Merger with Servier Pharmaceuticals
Amended material disclosure
Investor Presentation
Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Outlook and Revenue Guidance
Completes Acquisition of Mersana Therapeutics
NOVEMBER 2025 Acquisition, Investor Presentation
Amended Annual Report
FY 2024
Q3
Q2
Q1
FY 2023
Tender Offer Statement by Third Party
Solicitation/Recommendation Statement
Tender Offer Statement by Issuer
Schedule 14D-9C Solicitation/Recommendation Statement Communication
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Amended Schedule 13G - Ownership Report
Amended Schedule 13D - Ownership Report
Statement of Changes in Beneficial Ownership
Notification Filed by a National Security Exchange
Amended Schedule 14D-9 Solicitation/Recommendation Statement
S-8 POS
Automatic Shelf Registration Statement